Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients

NCT01905592 is registered in ClinicalTrials.gov with Tesaro, Inc. as lead sponsor.

NCT NCT01905592
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01905592 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Lead sponsor
Tesaro, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
February 25, 2014
Completion date
October 26, 2021
Enrollment
216 (actual)
Sites
104

Conditions

As the registry lists them; a condition with its own page is linked.

brca1 gene mutation, brca2 gene mutation, carcinoma of breast, human epidermal growth factor 2 negative carcinoma of breast, neoplasms, breast, ovarian neoplasms